Safety and Effectiveness of Ciprofol in Cardiac Surgery Anesthesia

Last updated: June 6, 2023
Sponsor: Le Yu
Overall Status: Active - Recruiting

Phase

N/A

Condition

Anesthesia

Treatment

Propofol injection

ciprofol injection

Clinical Study ID

NCT05892471
2022.8.1-2023.8.1
  • Ages 55-75
  • All Genders

Study Summary

Ciprofol, a novel intravenous general anesthetic with a chemical structure akin to propofol, boasts significantly enhanced potency. It offers a rapid onset, reduced incidence of injection pain, and minor impact on the cardiovascular system. However, clinical research regarding ciprofol's use for anesthesia induction in cardiac surgery remains limited. The investigators want to assesse the safety and effectiveness of ciprofol in cardiac surgery anesthesia

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Elective surgery patients
  2. Aged 55 to 75
  3. New York Heart Association class II or III cardiac functions
  4. Median sternotomy approach for coronary artery bypass grafting or heart valvereplacement procedures.

Exclusion

Exclusion Criteria:

  1. With a history of benzodiazepine allergy
  2. Significant liver or kidney insufficiency
  3. Coagulation dysfunction
  4. Neurological or psychiatric disorders
  5. Undergone major surgery within the past three months.

Study Design

Total Participants: 80
Treatment Group(s): 2
Primary Treatment: Propofol injection
Phase:
Study Start date:
August 01, 2022
Estimated Completion Date:
September 01, 2023

Connect with a study center

  • Shanghai East Hospital of Tongji University

    Shanghai, Shanghai 200120
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.